Logo image of ALEC

ALECTOR INC (ALEC) Stock Fundamental Analysis

USA - NASDAQ:ALEC - US0144421072 - Common Stock

3.18 USD
0 (0%)
Last: 9/23/2025, 8:00:00 PM
3.2 USD
+0.02 (+0.63%)
Pre-Market: 9/24/2025, 7:07:48 AM
Fundamental Rating

3

Taking everything into account, ALEC scores 3 out of 10 in our fundamental rating. ALEC was compared to 538 industry peers in the Biotechnology industry. Both the profitability and financial health of ALEC have multiple concerns. ALEC shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALEC had negative earnings in the past year.
ALEC had a negative operating cash flow in the past year.
ALEC had negative earnings in each of the past 5 years.
ALEC had negative operating cash flow in 4 of the past 5 years.
ALEC Yearly Net Income VS EBIT VS OCF VS FCFALEC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

ALEC has a Return On Assets of -32.35%. This is in the better half of the industry: ALEC outperforms 64.50% of its industry peers.
ALEC has a worse Return On Equity (-161.98%) than 63.75% of its industry peers.
Industry RankSector Rank
ROA -32.35%
ROE -161.98%
ROIC N/A
ROA(3y)-21.11%
ROA(5y)-21.34%
ROE(3y)-84.42%
ROE(5y)-67.29%
ROIC(3y)N/A
ROIC(5y)N/A
ALEC Yearly ROA, ROE, ROICALEC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALEC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALEC Yearly Profit, Operating, Gross MarginsALEC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALEC has more shares outstanding than it did 1 year ago.
ALEC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALEC has a worse debt to assets ratio.
ALEC Yearly Shares OutstandingALEC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ALEC Yearly Total Debt VS Total AssetsALEC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -3.07, we must say that ALEC is in the distress zone and has some risk of bankruptcy.
ALEC has a Altman-Z score of -3.07. This is comparable to the rest of the industry: ALEC outperforms 45.91% of its industry peers.
A Debt/Equity ratio of 0.13 indicates that ALEC is not too dependend on debt financing.
ALEC's Debt to Equity ratio of 0.13 is on the low side compared to the rest of the industry. ALEC is outperformed by 65.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -3.07
ROIC/WACCN/A
WACC9.84%
ALEC Yearly LT Debt VS Equity VS FCFALEC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

ALEC has a Current Ratio of 3.78. This indicates that ALEC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.78, ALEC perfoms like the industry average, outperforming 44.05% of the companies in the same industry.
A Quick Ratio of 3.78 indicates that ALEC has no problem at all paying its short term obligations.
ALEC has a Quick ratio (3.78) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.78
Quick Ratio 3.78
ALEC Yearly Current Assets VS Current LiabilitesALEC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.56% over the past year.
Looking at the last year, ALEC shows a very strong growth in Revenue. The Revenue has grown by 46.80%.
Measured over the past years, ALEC shows a very strong growth in Revenue. The Revenue has been growing by 36.53% on average per year.
EPS 1Y (TTM)35.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)46.8%
Revenue growth 3Y-21.4%
Revenue growth 5Y36.53%
Sales Q2Q%-47.8%

3.2 Future

ALEC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.16% yearly.
ALEC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.02% yearly.
EPS Next Y-27.6%
EPS Next 2Y-6.34%
EPS Next 3Y11.36%
EPS Next 5Y11.16%
Revenue Next Year-74.23%
Revenue Next 2Y0.31%
Revenue Next 3Y5.35%
Revenue Next 5Y22.02%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALEC Yearly Revenue VS EstimatesALEC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ALEC Yearly EPS VS EstimatesALEC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALEC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALEC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALEC Price Earnings VS Forward Price EarningsALEC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEC Per share dataALEC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.34%
EPS Next 3Y11.36%

More info and screens

0

5. Dividend

5.1 Amount

ALEC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALECTOR INC

NASDAQ:ALEC (9/23/2025, 8:00:00 PM)

Premarket: 3.2 +0.02 (+0.63%)

3.18

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners81.2%
Inst Owner Change-9.71%
Ins Owners6.91%
Ins Owner Change2.29%
Market Cap321.85M
Analysts77.33
Price Target3.91 (22.96%)
Short Float %5.98%
Short Ratio4.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.59%
Min EPS beat(2)17.12%
Max EPS beat(2)36.06%
EPS beat(4)4
Avg EPS beat(4)42.78%
Min EPS beat(4)17.12%
Max EPS beat(4)96.92%
EPS beat(8)8
Avg EPS beat(8)34.76%
EPS beat(12)10
Avg EPS beat(12)31.28%
EPS beat(16)11
Avg EPS beat(16)0.31%
Revenue beat(2)1
Avg Revenue beat(2)81.51%
Min Revenue beat(2)-17.7%
Max Revenue beat(2)180.71%
Revenue beat(4)2
Avg Revenue beat(4)94.69%
Min Revenue beat(4)-17.7%
Max Revenue beat(4)219.92%
Revenue beat(8)5
Avg Revenue beat(8)53.86%
Revenue beat(12)7
Avg Revenue beat(12)118.81%
Revenue beat(16)8
Avg Revenue beat(16)89.71%
PT rev (1m)-8%
PT rev (3m)-24.59%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)21.03%
EPS NY rev (1m)0%
EPS NY rev (3m)18.34%
Revenue NQ rev (1m)-12.31%
Revenue NQ rev (3m)3.12%
Revenue NY rev (1m)5.52%
Revenue NY rev (3m)33.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.97
P/FCF N/A
P/OCF N/A
P/B 4.52
P/tB 4.52
EV/EBITDA N/A
EPS(TTM)-1.16
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS0.8
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.35%
ROE -161.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.11%
ROA(5y)-21.34%
ROE(3y)-84.42%
ROE(5y)-67.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.75%
Cap/Sales 0.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.78
Quick Ratio 3.78
Altman-Z -3.07
F-Score3
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)37.68%
Cap/Depr(5y)49.71%
Cap/Sales(3y)2.26%
Cap/Sales(5y)6.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y-27.6%
EPS Next 2Y-6.34%
EPS Next 3Y11.36%
EPS Next 5Y11.16%
Revenue 1Y (TTM)46.8%
Revenue growth 3Y-21.4%
Revenue growth 5Y36.53%
Sales Q2Q%-47.8%
Revenue Next Year-74.23%
Revenue Next 2Y0.31%
Revenue Next 3Y5.35%
Revenue Next 5Y22.02%
EBIT growth 1Y29.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.33%
EBIT Next 3Y12.79%
EBIT Next 5Y9.32%
FCF growth 1Y-11.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.77%
OCF growth 3YN/A
OCF growth 5YN/A